.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average consequence of 11 months, patients with metastatic gastrointestinal tumors who acquired biomarker-matched treatments based on distributing lump DNA profiling showed a more significant professional perk than those getting unmatched treatment.